Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia.

BACKGROUND: Information is lacking on long-term management of patients with acute coronary syndrome (ACS) and chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2).
OBJECTIVES: Our objectives were to describe antithrombotic management patterns and outcomes in patients with ACS with varying renal function from the EPICOR (long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients; NCT01171404) and EPICOR Asia (NCT01361386) studies.
METHODS: EPICOR and EPICOR Asia were prospective observational studies of patients who survived hospitalization for ACS and were enrolled at discharge in 28 countries across Europe, Latin America, and Asia. The studies were conducted from 2010 to 2013 and from 2011 to 2014, respectively. This analysis evaluated patient characteristics and oral antithrombotic management patterns and outcomes up to 2 years post-discharge according to admission eGFR: ≥ 90, 60-89, 30-59, or < 30 mL/min/1.73 m2.
RESULTS: Among 22,380 patients with available data, eGFR < 60 mL/min/1.73 m2 was observed in 16.7%. Patients with poorer renal function were older, were at greater cardiovascular risk, and had more prior cardiovascular disease and bleeding. Patients with CKD underwent fewer cardiovascular interventions and had more in-hospital cardiovascular and bleeding events. Dual antiplatelet therapy was less likely at discharge in patients with eGFR < 30 (82.3%) than in those with ≥ 90 (91.3%) mL/min/1.73 m2 and declined more sharply during follow-up in patients with low eGFR (p < 0.0001). An adjusted proportional hazards model showed that patients with lower eGFR levels had a higher risk of cardiovascular events and bleeding.
CONCLUSIONS: The presence of CKD in patients with ACS was associated with less aggressive cardiovascular management and an increased risk of cardiovascular events.

Key Points

Introduction

Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular disease (CVD), and patients with CKD presenting with an acute coronary syndrome (ACS), particularly those with more severe renal dysfunction, have higher rates of mortality, complications, and bleeding events [1-6]. According to data from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network (ACTION) registry in the USA, CKD (defined as estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2) is present in approximately 43% of patients presenting with non-ST-segment elevation (NSTE)-ACS (including NSTE myocardial infarction [NSTEMI] and unstable angina) and 31% of those with ST-segment elevation myocardial infarction (STEMI) [4].

Given the poorer prognosis for those with CKD, and the potential need for dose adjustment of some antithrombotic agents, guidelines recommend that eGFR be evaluated as soon as possible in patients presenting with ACS [7, 8]. However, the same guidelines offer little in the way of treatment guidance for patients with CKD because of the paucity of solid evidence in this regard as patients with severe renal dysfunction have been systematically excluded from many randomized clinical trials [9, 10]. There is evidence indicating that outcomes are better in patients with CKD who undergo early revascularization [11-13] and receive prolonged dual antiplatelet therapy (DAPT) during follow-up [14], but recent studies have suggested that they are largely undertreated compared with patients without CKD [4, 15–18]. Furthermore, there is minimal information on the effects of antithrombotic management patterns (AMPs) on long-term outcomes beyond 1 year from the index event [19].

EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients, NCT01171404) and EPICOR Asia (NCT01361386) were twin observational studies of patients surviving hospitalization for ACS who were followed-up for 2 years. The present analysis describes the association between long-term use of oral antiplatelet agents and clinical outcomes in patients with ACS with different degrees of renal function.

Materials and Methods

Patients

The EPICOR and EPICOR Asia study designs and baseline patient characteristics have been published previously [20, 21]. Both were multinational, observational, prospective cohort studies with 2-year follow-up periods [19]. EPICOR enrolled patients between September 2010 and March 2011 from 555 centers in 20 countries across Europe and Latin America, whereas EPICOR Asia enrolled patients between June 2011 and May 2012 from 218 centers in China, Hong Kong, India, Malaysia, Singapore, South Korea, Thailand, and Vietnam.

Patients who survived hospitalization for an ACS (STEMI, NSTEMI, or unstable angina) were eligible for inclusion if they were aged at least 18 years and were hospitalized within 24 h (EPICOR) or 48 h (EPICOR Asia) of symptom onset. For the present analysis, patients were also required to have a known level of renal function, defined by eGFR.

All patients were enrolled at discharge from hospital, which could be the original center to which they were admitted or another participating hospital to which they were transferred. Patients transferred to a non-participating hospital (and not transferred back again) were therefore excluded from the study. Other key exclusion criteria were “secondary” ACS (that is, precipitated by or occurring as a complication of surgery, trauma, percutaneous coronary intervention [PCI], or other reasons), any serious or severe comorbidities considered likely to limit life expectancy to less than 6 months, and prior enrollment in EPICOR or EPICOR Asia.

Objectives

The primary objective of EPICOR and EPICOR Asia was to describe acute and long-term AMPs in ACS survivors in a wide range of clinical settings and countries [20, 21]. The objectives of the present analysis were to describe patient characteristics, oral AMPs, and clinical outcomes over the 2-year follow-up period in patients with one of four different categories of renal function at hospital admission (baseline), defined as eGFR ≥ 90, 60–89, 30–59, or < 30 mL/min/1.73 m2. eGFR was calculated using the 2009 Chronic Kidney Disease Epidemiology Collaboration creatinine formula [22]: where κ is 0.7 for females and 0.9 for males, α is − 0.329 for females and − 0.411 for males, and sCr is serum creatinine.

In this report, CKD is defined as patients with eGFR< 60 mL/min/1.73 m2.

Baseline and In-Hospital Variables

Collected variables included baseline demographic data, socio-economic factors, medical history (including prior CVD and non-CVD), major bleeding events within 6 months prior to the index event, medications, procedures (PCI and coronary artery bypass graft [CABG]), laboratory test results, and EuroQol 5-Dimensions (EQ-5D) simple score for quality of life. Data on medication, procedures, and outcomes (cardiovascular and bleeding events) during initial hospitalization were also recorded, as were discharge medications (including number and type of oral antiplatelet agents, anticoagulants, and other cardiovascular medications).

Outcomes

Clinical events analyzed during follow-up were death; nonfatal myocardial infarction (MI); nonfatal stroke; composite of death, MI, or stroke; first major bleeding; any bleeding; unstable angina; any coronary revascularization (PCI or CABG); and heart failure.

Statistical Analysis

Patient characteristics, AMPs, and clinical outcomes are summarized by eGFR category, showing the number and percentage of patients or mean and standard deviation for each variable, with p values from a chi-squared test for categorical variables or one-way analysis of variance for continuous variables used to assess differences between them; eGFR group was treated as a categorical variable for the purposes of these comparisons. Cox proportional hazards modeling was used to examine the association between clinical outcomes (composite cardiovascular endpoint, death, MI, ischemic stroke, bleeding, and major bleeding) and the degree of renal function (eGFR 60–89, 30–59, and < 30 with eGFR ≥ 90 mL/min/1.73 m2), estimating hazard ratios (HRs) and their 95% confidence interval (CI) for each outcome. To obtain adjusted estimates of these associations, the Cox model was fitted containing terms for age (per 10 years), sex, final diagnosis of index event, EQ-5D overall health status at discharge, in-hospital cardiac events, previous chronic obstructive pulmonary disease, previous peripheral vascular disease, prior PCI or CABG, admission glucose (< 160/≥ 160 mg/dL; cardiovascular events only), admission hemoglobin (< 13/≥ 13 g/dL), and diuretics at discharge, for subjects with data available. All p values are two-sided, with values < 0.05 considered statistically significant. All statistical analyses were performed using SAS version 9.3 or later.

Results

Of 23,490 patients enrolled in EPICOR (n = 10,568) and EPICOR Asia (n = 12,922), 22,380 had eGFR data available and were included in the present analysis. Baseline patient demographic and clinical characteristics are summarized by eGFR category in Table 1 and in eTable 1 in the electronic supplementary material (ESM). The majority of patients had eGFR ≥ 60 mL/min/1.73 m2 (41.9% eGFR ≥ 90 and 41.4% eGFR 60–89), whereas 16.7% had lower levels of renal function (14.5% eGFR 30–59 and 2.2% eGFR < 30). Patients with poorer renal function were older, with a lower level of education, and the percentage of male patients declined along with eGFR status. There were also differences across the country/region groups, with rates of eGFR < 30 mL/min/1.73 m2 ranging from 1.4% in China and Eastern Europe to 5.6% in Thailand, Vietnam, and Malaysia. Those same countries/regions also had the highest and lowest rates, respectively, of eGFR ≥ 90 mL/min/1.73 m2. Lower renal function was more often associated with a higher cardiovascular risk profile (with the single exception of smoking) and a greater likelihood of prior CVD, anemia, bleeding, Killip class > I, lower hemoglobin, and higher blood glucose levels. In the lowest eGFR group, more patients had NSTEMI than STEMI (46.8 vs. 37.0%). Overall, 1568 of 11,281 (12.9%) patients with STEMI and 1438 of 6285 (22.9%) patients with NSTEMI had CKD (eGFR < 60 mL/min/1.73 m2).

Table 1

Baseline characteristics and clinical presentation of patients with acute coronary syndrome, stratified by eGFR category at admission

Characteristics and presentation	eGFR (mL/min/1.73 m2)				p valuea
	≥ 90(n = 9372)	60‒89(n = 9260)	30‒59(n = 3250)	< 30(n = 498)
Age, years	54.5 ± 9.6	63.7 ± 11.1	70.1 ± 10.4	69.7 ± 10.9	< 0.0001
Age group, years
≤ 59	6451 (68.8)	3291 (35.5)	514 (15.8)	90 (18.1)	< 0.0001
60–74	2783 (29.7)	4329 (46.8)	1488 (45.8)	220 (44.2)
≥ 75	138 (1.5)	1640 (17.7)	1248 (38.4)	188 (37.8)
Male	7619 (81.3)	6915 (74.7)	2098 (64.4)	319 (64.1)	< 0.0001
eGFR, mL/min/1.73 m2b	101.9 ± 9.2	76.9 ± 8.5	48.6 ± 7.9	19.9 ± 7.6	NA
Peak creatinine, mg/dL	0.8 ± 0.2	1.0 ± 0.3	1.5 ± 0.5	3.8 ± 2.2	< 0.0001
Creatinine increase of 0.5 mg/dL or 25% from admission to discharge	17 (0.2)	17 (0.2)	12 (0.4)	1 (0.2)	< 0.0001
BMI, kg/m2	26.0 ± 4.2	26.0 ± 4.3	25.9 ± 4.6	25.6 ± 4.7	0.317
≤ 25	3838 (45.0)	3758 (44.9)	1332 (46.5)	210 (50.1)	0.090
Index diagnosis					< 0.0001
STEMI	4990 (53.2)	4409 (47.6)	1384 (42.6)	184 (37.0)
NSTEMI	2206 (23.5)	2641 (28.5)	1205 (37.1)	233 (46.8)
Unstable angina	2176 (23.2)	2210 (23.9)	661 (20.3)	81 (16.3)
Medical history
Hypertension	4356 (47.0)	5272 (57.5)	2337 (72.4)	417 (84.1)	< 0.0001
Diabetes	1779 (19.2)	2146 (23.5)	1094 (34.0)	262 (53.0)	< 0.0001
Hypercholesterolemia	2535 (28.1)	2923 (32.9)	1130 (36.4)	184 (39.1)	< 0.0001
Current/past smoking	6247 (68.8)	5093 (56.9)	1575 (50.2)	209 (44.7)	< 0.0001
Prior MI	939 (10.2)	1257 (13.9)	703 (22.2)	144 (29.3)	< 0.0001
Prior PCI	785 (8.5)	1034 (11.4)	502 (15.8)	96 (19.5)	< 0.0001
Prior CABG	187 (2.0)	303 (3.3)	230 (7.2)	39 (7.9)	< 0.0001
Heart failure	131 (1.4)	335 (3.79)	258 (8.1)	79 (16.1)	< 0.0001
Atrial fibrillation	105 (1.2)	319 (3.6)	199 (6.4)	37 (7.2)	< 0.0001
Stroke	246 (2.7)	483 (5.3)	274 (8.6)	47 (9.5)	< 0.0001
COPD	270 (2.9)	419 (4.6)	256 (8.0)	36 (7.3)	< 0.0001
Anemia	35 (0.4)	84 (0.9)	86 (2.7)	92 (18.6)	< 0.0001
Major bleeding within previous 6 months	35 (0.4)	41 (0.5)	30 (0.9)	9 (1.8)	< 0.0001
Killip class > I	951 (13.3)	1342 (18.6)	764 (29.1)	182 (43.7)	< 0.0001
Initial laboratory measures
Hemoglobin, g/L	141.9 (17.0)	138.6 (17.8)	130.6 (19.9)	115.4 (22.1)	< 0.0001
< 110	307 (3.3)	438 (4.8)	436 (13.9)	189 (40.0)	< 0.0001
White blood cell count, cells/µL	9919.6 ± 4492.3	9559.6 ± 4219.1	9931.7 ± 4699.0	10,581.5 ± 6662.3	< 0.0001
Blood glucose, mg/dL	135.3 ± 59.4	139.8 ± 63.3	156.5 ± 2.7	177.3 ± 117.5	< 0.0001
In-hospital cardiac studies
Echocardiography	7636 (81.9)	7445 (81.0)	2575 (80.0)	377 (76.5)	0.004
Continuous LVEF measurement	6222 (66.4)	5830 (63.0)	1984 (61.1)	301 (60.4)	< 0.0001
LVEF (last pre-discharge), %	54.4 ± 11.4	52.9 ± 12.2	50.4 ± 13.3	47.2 ± 13.5	< 0.0001
LVEF < 0.30	98 (1.6)	157 (2.7)	109 (5.5)	24 (8.0)	< 0.0001
Cardiac catheterization	8149 (87.1)	7494 (81.3)	2354 (72.7)	285 (57.3)	< 0.0001
Number of diseased vessels					< 0.0001
0	537 (6.7)	457 (6.3)	154 (6.7)	15 (5.4)
1	3484 (43.6)	2700 (37.1)	691 (30.2)	77 (27.6)
2	2140 (26.8)	2081 (28.6)	659 (28.8)	74 (26.5)
3	1828 (22.9)	2044 (28.1)	783 (34.2)	113 (40.5)
Left main diseasec	918 (11.5)	915 (12.6)	393 (17.3)	51 (18.8)	< 0.0001

Data are presented as mean ± standard deviation or n (%) unless otherwise indicated

BMI body mass index, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, eGFR estimated glomerular filtration rate, LVEF left ventricular ejection fraction, MI myocardial infarction, NA not applicable, NSTEMI non-ST-segment elevation MI, PCI percutaneous coronary intervention, STEMI ST-segment elevation MI

ap value taken from a chi-squared test (categorical variables) or one-way analysis of variance (continuous variables). eGFR group was treated as a categorical variable, looking at differences between the four groups

bCalculated based on initial creatinine

cPercentage of patients with data available

Mean left ventricular ejection fraction (LVEF) decreased significantly across the four renal function groups, with an increasing proportion of patients with LVEF < 30% (increasing from 1.6% in the highest renal function group to 8.0% in the lowest) (Table 1). Patients with eGFR < 60 mL/min/1.73 m2 were also more likely to have multiple diseased vessels on coronary angiography, e.g., 22.9% of patients with eGFR ≥ 90 and 40.5% with eGFR < 30 mL/min/1.73 m2 had three diseased vessels and were more likely to have left main coronary artery disease (11.5 and 18.8%, respectively).

Management and Outcomes

Despite presenting a higher risk, patients with CKD were less likely to undergo coronary angiography, PCI, or CABG during initial hospitalization and more likely to experience in-hospital cardiovascular events and bleeding (Table 2). Similar patterns of less aggressive management and increased event rates with lower eGFR were observed for patients in each ACS diagnostic category (eTable 2 in the ESM). Patients with poorer renal function were also significantly less likely to be discharged on DAPT (aspirin plus a P2Y12 inhibitor), ranging from 91.3% of patients with eGFR ≥ 90 mL/min/1.73 m2 to 82.3% of those with eGFR < 30 (p < 0.0001; Table 3). Patients with eGFR < 30 were also less likely to receive angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers. Similarly, patients with CKD were less frequently prescribed β-blockers, but more likely to receive anticoagulants, calcium channel blockers, diuretics, aldosterone inhibitors, and nitrates, whereas statin use was similar across the renal function groups (Table 3, eTable 3 in the ESM).

Table 2

In-hospital management and clinical events, stratified by eGFR category

	eGFR (mL/min/1.73 m2)				p valuea
	≥ 90(n = 9372)	60–89(n = 9260)	30–59(n = 3250)	< 30(n = 498)
In-hospital management
Primary PCI	3540 (38.0)	3126 (34.0)	927 (28.8)	98 (19.9)	< 0.0001
Any PCI	6836 (73.4)	6161 (67.1)	1830 (56.8)	219 (44.5)	< 0.0001
Any stent	6836 (73.4)	6161 (67.1)	1830 (56.8)	219 (44.5)	< 0.0001
CABG	130 (1.4)	169 (1.8)	54 (1.7)	7 (1.4)	0.119
In-hospital outcomes
Any cardiovascular eventsb	1057 (11.3)	1584 (17.1)	764 (23.5)	153 (30.7)	< 0.0001
New myocardial infarction	215 (2.3)	263 (2.8)	100 (3.1)	15 (3.0)	0.035
Heart failure or cardiogenic shock	366 (3.9)	646 (7.0)	401 (12.3)	92 (18.5)	< 0.0001
Arrhythmias	424 (4.5)	704 (7.6)	346 (10.7)	59 (11.9)	< 0.0001
Stroke	13 (0.1)	19 (0.2)	14 (0.4)	3 (0.6)	0.005
Bleeding events	175 (1.9)	257 (2.8)	143 (4.4)	25 (5.0)	< 0.0001
Major bleeding	32 (0.3)	61 (0.7)	39 (1.2)	11 (2.2)	< 0.0001
Procedure-related bleeding	94 (1.0)	140 (1.5)	59 (1.8)	10 (2.0)	< 0.001

Data are presented as n (%) unless otherwise indicated

CABG coronary artery bypass graft, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention

ap value for trend test

bNonfatal cardiovascular events, including those listed below this label

Table 3

Discharge medication and clinical outcomes after 2 yearsa of follow-up, stratified by eGFR category

Discharge medication and clinical outcomes	eGFR (mL/min/1.73 m2)				p value
	≥ 90(n = 9372)	60–89(n = 9260)	30–59(n = 3250)	< 30(n = 498)
Discharge medication
No antiplatelet	73 (0.8)	98 (1.1)	55 (1.7)	14 (2.8)	< 0.0001
Aspirin only	501 (5.4)	545 (5.9)	223 (6.9)	36 (7.2)	0.007
P2Y12 inhibitor only	164 (1.8)	261 (2.8)	101 (3.1)	23 (4.6)	< 0.0001
DAPT (aspirin and P2Y12 inhibitor)	8553 (91.3)	8210 (88.7)	2795 (86.0)	410 (82.3)	< 0.0001
Any anticoagulant	168 (1.8)	300 (3.2)	162 (5.0)	22 (4.4)	< 0.0001
ACEi/ARB	6355 (68.0)	6613 (71.6)	2280 (70.4)	258 (51.8)	< 0.0001
β-blocker	7320 (78.3)	7093 (76.8)	2439 (75.3)	366 (73.8)	< 0.001
Statin	6761 (72.3)	6835 (74.1)	2408 (74.3)	359 (72.2)	0.024
Calcium channel blocker	1007 (10.8)	1259 (13.7)	555 (17.2)	140 (28.3)	< 0.0001
Any diuretic	854 (9.1)	1489 (16.2)	938 (29.0)	218 (44.0)	< 0.0001
Aldosterone antagonist	586 (6.3)	831 (9.0)	381 (11.8)	45 (9.1)	< 0.0001
Nitrate	316 (6.1)	421 (9.1)	170 (10.8)	44 (17.1)	< 0.0001
Clinical events
Death	227 (2.4)	484 (5.2)	403 (12.4)	110 (22.1)	< 0.0001
Nonfatal MI	186 (2.0)	239 (2.6)	138 (4.3)	30 (6.0)	< 0.0001
Nonfatal ischemic stroke	66 (0.7)	81 (0.9)	39 (1.2)	9 (1.8)	0.007
Death/nonfatal MI/nonfatal ischemic stroke	446 (4.8)	736 (8.0)	517 (15.9)	131 (26.3)	< 0.0001
Any coronary revascularization (any PCI/CABG)	890 (9.5)	854 (9.2)	332 (10.2)	49 (9.8)	0.418
Heart failure	295 (3.2)	537 (5.8)	337 (10.4)	73 (14.9)	< 0.0001
Any bleeding	446 (4.8)	465 (5.0)	184 (5.7)	31 (6.2)	0.130
Major bleeding	22 (0.2)	27 (0.3)	20 (0.6)	2 (0.4)	0.010

Data are presented as n (%) unless otherwise indicated

ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, CABG coronary artery bypass graft, DAPT dual antiplatelet therapy, eGFR estimated glomerular filtration rate, MI myocardial infarction, PCI percutaneous coronary intervention

aFinal follow-up visit was at 23 months

The average duration of DAPT ranged from 16.7 months in the eGFR < 30 mL/min/1.73 m2 category to 19.8 months in the eGFR ≥ 90 category (p < 0.0001). Use of DAPT during long-term follow-up declined consistently across the eGFR groups and declined over time (Fig. 1). At 12 months, 57.0% of patients with eGFR < 30 mL/min/1.73 m2 and 78.0% of those with eGFR ≥ 90 mL/min/1.73 m2 were still receiving DAPT. At the final follow-up visit, 38.8% of patients in the eGFR < 30 category continued to receive DAPT compared with 57.5% in the highest eGFR group. A similar pattern was observed across the three ACS diagnostic groups (eTable 3 in the ESM).

Fig. 1

Proportion of patients on DAPT at each visit according to eGFR group over 2 years. *p < 0.0001 across eGFR categories at each timepoint. DAPT dual antiplatelet therapy, eGFR estimated glomerular filtration rate

Rates of death, nonfatal MI, nonfatal stroke, heart failure, and bleeding during long-term follow-up were also higher in patients with lower eGFR, although overall coronary revascularization rates did not differ significantly between the categories (Table 3, eTable 3 in the ESM).

In the unadjusted proportional hazards model, there was a clear trend for lower eGFR levels to be associated with an increased risk of the composite cardiovascular endpoint and individual endpoints of death, MI, ischemic stroke, bleeding, and major bleeding over the 2-year follow-up period (Fig. 2). The crude HR for all-cause death, in particular, was much higher when comparing patients with eGFR < 30 versus those with eGFR ≥ 90 mL/min/1.73 m2 (10.71 [95% CI 8.53–13.45]) than the equivalent comparison for patients with eGFR 60–89 mL/min/1.73 m2 (2.20 [95% CI 1.88–2.58]). After adjustment for potential confounding factors, the HRs showed a similar consistent trend across the eGFR groups for all outcomes except major bleeding.

Fig. 2

Risk of cardiovascular events by eGFR category, relative to eGFR ≥ 90 mL/min/1.73 m2, during the 2-year follow-up period: a eGFR < 30, b eGFR 30–59, and c eGFR 60–89 mL/min/1.73 m2. *Model adjusted for age (per 10 years), sex, final diagnosis of index event (UA/STEMI/NSTEMI), EQ-5D overall health state at discharge, in-hospital cardiovascular events, previous chronic obstructive pulmonary disease/lung disease, previous peripheral vascular disease, prior PCI or CABG, admission hemoglobin (< 13/≥ 13 g/dL), and diuretics at discharge. HRs and 95% CIs relative to eGFR ≥ 90 mL/min/1.73 m2,

taken from a Cox proportional hazards model for time to the endpoint in question, containing eGFR (< 30, 30–59, 60–89, and ≥ 90) as a covariate. CABG coronary artery bypass graft, CI confidence interval, eGFR estimated glomerular filtration rate, EQ-5D EuroQol 5-Dimensions, HR hazard ratio, MI myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction, UA unstable angina

Discussion

These data from EPICOR and EPICOR Asia indicate that patients with renal dysfunction less frequently underwent early PCI or CABG and were less likely to be discharged on DAPT, with decreasing use across the eGFR groups as renal function declined. The results are in keeping with those of other studies [4, 15–18] and despite the known association between CKD and increased risk of CVD, ACS, and subsequent in-hospital events or death [23-26]. We also showed that in-hospital and long-term mortality, cardiovascular and bleeding event rates were higher in patients with CKD, particularly in those with eGFR < 30 mL/min/1.73 m2. Thus, although patients with poorer renal function were less likely to receive DAPT at discharge and more likely to discontinue it early, they still had higher bleeding rates than those with “normal” renal function. This is the most likely reason for the apparent “undertreatment” with antithrombotics in this population.

Less than 20% of the ACS survivors enrolled in these studies had eGFR < 60, which is somewhat lower than the 31–43% reported previously in the ACTION registry, although it should be noted that the ACTION cohort included patients who died in hospital [4]. Furthermore, it was only in the lowest eGFR group (< 30 mL/min/1.73 m2) that the proportion of patients with STEMI was exceeded by those with NSTEMI. These discrepancies may result from the large and diverse population included in our cohort [27, 28]. Overall, however, our population characteristics aligned with those observed elsewhere in terms of enhanced cardiovascular risk [1-6].

There is limited guidance on the use of PCI and antiplatelet therapy in patients with ACS and CKD. Neither the 2013 American College of Cardiology Foundation/American Heart Association (AHA) STEMI guidelines nor the 2015 American College of Cardiology (ACC)/AHA/Society for Cardiovascular Angiography and Interventions guidelines for use of PCI in patients with STEMI refer to renal function [29, 30]. European Society of Cardiology guidelines for the management of patients with STEMI and NSTE-ACS (specifically referred to in the guidelines’ web-addenda) state that choice and dose of antithrombotic agents need to be considered carefully in the context of bleeding risk in patients with renal dysfunction, but no dose adjustment is required for aspirin or the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor [7, 8]. The authors of a recent meta-analysis and review of prasugrel or ticagrelor in patients with CKD and ACS concluded that the newer antiplatelet agents were associated with a reduced rate of major adverse cardiovascular events compared with clopidogrel, without an increased bleeding risk [31, 32]. AHA/ACC NSTE-ACS guidelines note that hypo-responsiveness to clopidogrel may be an issue in patients with CKD and that ticagrelor may be a better alternative based on trial results [33]. Data from the PLATO (Platelet Inhibition and Patient Outcomes) trial confirmed the benefit of ticagrelor over clopidogrel to reduce the risk of further cardiovascular events in the 12 months following an ACS in patients with CKD [34, 35]. Nevertheless, evidence from the TRANSLATE-ACS (Treatment with ADP Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) study suggested that the risk of moderate or severe bleeding with higher-potency P2Y12 inhibitors increased with the severity of CKD and that treatment interruptions or a switch to clopidogrel may be more likely in those with more advanced disease [36].

Our analysis showed that DAPT duration during follow-up was shorter in patients with CKD and decreased across the four categories of eGFR at each of the 6-month time points over the 2-year period, but still exceeded 12 months in a significant proportion of patients. A similar pattern was observed in the overall EPICOR and EPICOR Asia studies, with the majority of patients continuing to receive DAPT beyond 12 months [37-40]. Recent data from the large SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry showed that prolonged use of DAPT (compared with 3 months, duration) following an ACS is associated with a lower risk of death, stroke, and MI in patients with or without CKD, with a similar bleeding risk in each case [14].

During the 2-year follow-up period in EPICOR and EPICOR Asia, patients with lower eGFR had higher rates of adverse outcomes, including death, nonfatal MI, nonfatal stroke, and bleeding. For example, 2-year mortality was 22.1% in patients in the lowest renal function group compared with 2.4% in the highest group and 5.2% in the overall EPICOR Asia population [41]. HRs for the composite and individual cardiovascular endpoints and death were higher in patients with poorer renal function on both unadjusted and adjusted analysis. Similar findings have been reported elsewhere in Asian populations [42, 43]. Of note, this evidence is relevant because Asian populations have historically been under-represented in both observational and randomized studies [44].

There are several limitations to this analysis of data from the EPICOR and EPICOR Asia studies [19, 27, 37–41, 45–52]. First, considerations inherent to the analysis of observational data must be taken into account, such as a potential patient selection bias in terms of differences in DAPT patterns and clinical outcomes across the eGFR groups. Second, the studies excluded data from non-survivors of the index event and from patients transferred to a non-participating hospital [45]. Another limitation is the lack of information on specific reasons for non-use of antithrombotic agents at discharge or for discontinuation of DAPT during long-term follow-up [38]. Third, the study did not track how renal function changes over time nor, therefore, the degree to which this impacted on further treatment decisions (e.g., stopping DAPT or undergoing subsequent intervention) or long-term outcomes. Finally, the use of quality indicators [52] in this patient subgroup has not been validated and may be challenging.

In conclusion, the presence of CKD in patients with ACS in the EPICOR and EPICOR Asia studies was associated with less aggressive cardiovascular management and an increased risk of cardiovascular events and bleeding, both in hospital and during long-term follow-up, with a consistent pattern across the three ACS diagnostic categories. Patients with ACS and renal dysfunction, therefore, require careful assessment and tailored short- and long-term antithrombotic management, including selection of appropriate oral antiplatelet therapy, to minimize the risk of adverse clinical events. This recommendation may be particularly pertinent for patients in geographical areas with an apparently higher prevalence of renal dysfunction (Thailand/Vietnam/Malaysia and Latin America) and in patients with poorer socio-economic indicators, such as rural residence, no formal education, and lack of medical insurance. Future real-world evidence studies looking at long-term antithrombotic management strategies and outcomes of patients with ACS should be designed to take such issues into consideration.

Below is the link to the supplementary information.

Supplementary file1 (DOCX 45 kb)

Data from EPICOR and EPICOR Asia, twin international observational studies with a 2-year follow-up period, showed that chronic kidney disease (estimated glomerular filtration rate < 60 mL/min/1.73 m2) was associated with less aggressive management and an increased risk of cardiovascular events and bleeding, across all three types of acute coronary syndromes (ACS) (ST-segment elevation myocardial infarction [STEMI], non-STEMI, and unstable angina).

Patients with ACS and renal dysfunction require careful assessment and tailored short- and long-term antithrombotic management to reduce adverse clinical event rates.